Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations
- PMID: 34566442
- PMCID: PMC8461119
- DOI: 10.1177/11795735211036576
Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations
Abstract
Stroke patients with spasticity usually require long-lasting care and interventions but frequently report that outpatient and community treatment is limited, reflecting a significant unmet need in health and social care provision. Rehabilitation and spasticity management services are essential for patient recovery, with improvements in both activity and participation reducing the burden on patients, family and society. Current clinical guidance provides scope for improvements in both post-stroke management and spasticity prevention. However, access to specialist services can be limited and the patient journey does not always match national recommendations. Identification of spasticity and its predictors and lack of subsequent referral to rehabilitation or specialist spasticity services are key issues in the management of post-stroke spasticity. Implementation of a traffic light classification system prioritises patients at an increased risk of spasticity and promotes early and consistent management across the spectrum of primary and secondary care. The proposed system is based on clinical evidence, expert consensus and recent clinical guidelines. It provides simple and straightforward criteria for management, multidisciplinary consultation and referral to specialist spasticity services, with patients allocated by monitoring requirements and a low (green/periodic monitoring), medium (amber/routine referral) or high risk (red/urgent referral) of spasticity.
Keywords: consensus; guidelines; recommendation; spasticity; stroke.
© The Author(s) 2021.
Conflict of interest statement
Declarations of Conflicting Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Conflicting interests: GB has received educational support and honoraria from Allergan, Ipsen and Merz. GS has received Speaker fees from Bayer, BI, BMS, Covedien, Grunenthal, Medtronic, MSD and Pfizer. Advisory board fees from Allergan, Amgen, Bayer, BI and Pfizer. Travel expenses from, Bayer, BI, Medtronic, Merc, MSD and Pfizer. He has no personal financial interest in any of the material mentioned in this article. SA has a specific interest in outcomes evaluation and has published on the use of Goal Attainment Scaling in this context, as well as a number of the other standardised measures such as the Arm and Leg activity measures. All of these tools are freely available. He has received educational support and honoraria from Allergan, Ipsen and Mertz, who manufacture botulinum toxin products and has received research grants from Ipsen. He has no personal financial interest in any of the material mentioned in this article. RA has received educational support and honoraria from Allergan, and educational support from Ipsen and Mertz, who all manufacture botulinum toxin products. She has no personal financial interest in any of the material mentioned in this article. DH has contributed to Allergan, Ipsen and Merz educational materials.
Figures
References
-
- Hall P, Williams D, Hickey A, et al.Access to rehabilitation at six months post stroke: A Profile from the action on secondary prevention interventions and rehabilitation in stroke (ASPIRE-S) study. Cerebrovasc Dis 2016;42:247-254. - PubMed
-
- Enderby P, Pandyan A, Bowen A, et al.Accessing rehabilitation after stroke – a guessing game? Disabil Rehabil, 2017;39(7):709-713. - PubMed
-
- Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol 2010;9:105-118. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
